

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
February 3rd, 2026

| | |
|-----------------|---|
| Company: | Chordia Therapeutics Inc. |
| Representative: | Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market) |
| Contact: | Chief Financial Officer Masaru Okatani |

Notice Concerning Change of Major Shareholder

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake) (“Chordia”) announces that there has been a change in the major shareholder of the Company as of January 23, 2026, as described below.

This change resulted from an increase in the total number of voting rights of all shareholders due to the exercise of the Chordia’s 9th Series Stock Acquisition Rights (with a variable exercise price provision), as well as an increase in voting rights arising from the exercise of other stock acquisition rights separate from the 9th Series Stock Acquisition Rights. As a result, the ratio of voting rights held by the shareholder described below fell below 10% of the total voting rights of all shareholders, and such shareholder no longer qualifies as a major shareholder.

1. Background for the change

As a result of the issuance of new shares upon the exercise of the Chordia’s 9th Series of Share Acquisition Rights (with an exercise price adjustment clause), the total number of voting rights of all shareholders increased. Consequently, the ratio of voting rights held by the shareholder listed below fell below 10% of the total voting rights of all shareholders, and such shareholder no longer qualifies as a major shareholder.

2. Overview of the Shareholder Subject to Change

| | | |
|-----|-------------------------|--|
| (1) | Name | New Life Science I Investment Limited Partnership |
| (2) | Location | Toranomon 40MT Building, 5-13-1 Toranomon, Minato-ku, Tokyo, Japan |
| (3) | General Partner | Shinsei Capital Partners, Ltd. CEO Manabu Nakamura |
| (4) | Description of business | Venture Capital |

3. Number of voting rights (number of shares) held by the shareholder and its ratio to the voting rights held by all shareholders before and after the change.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

ir@chorditherapeutics.com



| | Number of voting rights (Number of shares held) | Ratio of voting rights held | Ranking among major shareholders |
|---|---|-----------------------------|----------------------------------|
| Before the change (As of Aug 31st, 2025) | 72,521 units (7,252,100 shares) | 10.51% | 2nd |
| After the change | 72,521 units (7,252,100 shares) | 9.99% | 2nd |

- *1 The above figures represent the estimated number and ratio of voting rights reasonably calculated by the Company based on its understanding of the status of the exercise of 9th Series of Share Acquisition Rights, and the Company has not confirmed the actual number of shares or voting rights held by New Life Science No.1 Investment Limited Liability Partnership.
- *2 The “Number of voting rights (number of shares held)” before the change is based on the shareholder register as of August 31, 2025.
- *3 The “Ratio of voting rights held” before the change is calculated based on the total number of voting rights of 689,787 as of August 31, 2025, and rounded down to the second decimal place.
- *4 The “Ratio of voting rights held” after the change is calculated using, as the denominator, the total number of voting rights obtained by adding 36,331 voting rights—consisting of 33,131 voting rights increased as a result of the exercise of the Company’s 9th Series of Stock Acquisition Rights up to January 23, 2026, and 3,200 voting rights increased as a result of exercises by individuals—to the total number of 689,787 voting rights used in calculating the ratio of voting rights held to the total number of voting rights before the change.

4. Future outlook

This change will have no impact on the Chordia's management and business performance.